Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 30;9(10):3173.
doi: 10.3390/jcm9103173.

Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice

Dean R P P Chan Pin Yin  1 , Gert-Jan A Vos  1 , Niels M R van der Sangen  2 , Ronald Walhout  3 , R Melvyn Tjon Joe Gin  4 , Deborah M Nicastia  5 , Jorina Langerveld  6 , Daniël M F Claassens  1 , Marieke E Gimbel  1 , Jaouad Azzahhafi  1 , Willem L Bor  1 , Tom Oirbans  1 , Johan Dekker  1 , Georgios J Vlachojannis  7 , Rutger J van Bommel  8 , Yolande Appelman  9 , José P S Henriques  2 , Wouter J Kikkert  10 , Jurriën M Ten Berg  1
Affiliations

Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice

Dean R P P Chan Pin Yin et al. J Clin Med. .

Abstract

Diagnostic and treatment strategies for acute coronary syndrome have improved dramatically over the past few decades, but mortality and recurrent myocardial infarction rates remain high. An aging population with increasing co-morbidities heralds new clinical challenges. Therefore, in order to evaluate and improve current treatment strategies, detailed information on clinical presentation, treatment and follow-up in real-world patients is needed. The Future Optimal Research and Care Evaluation in patients with Acute Coronary Syndrome (FORCE-ACS) registry (ClinicalTrials.gov Identifier: NCT03823547) is a multi-center, prospective real-world registry of patients admitted with (suspected) acute coronary syndrome. Both non-interventional and interventional cardiac centers in different regions of the Netherlands are currently participating. Patients are treated according to local protocols, enabling the evaluation of different diagnostic and treatment strategies used in daily practice. Data collection is performed using electronic medical records and quality-of-life questionnaires, which are sent 1, 12, 24 and 36 months after initial admission. Major end points are all-cause mortality, myocardial infarction, stent thrombosis, stroke, revascularization and all bleeding requiring medical attention. Invasive therapy, antithrombotic therapy including patient-tailored strategies, such as the use of risk scores, pharmacogenetic guided antiplatelet therapy and patient reported outcome measures are monitored. The FORCE-ACS registry provides insight into numerous aspects of the (quality of) care for acute coronary syndrome patients.

Keywords: acute coronary syndrome; antiplatelet therapy; multicenter registry.

PubMed Disclaimer

Conflict of interest statement

J.P.S.H. has received unrestricted grants from AstraZeneca; W.J.K. has received research grants and speaker fees from AstraZeneca; J.M.t.B. has received research grants from ZonMw and AstraZeneca and Advisory/consulting/speaker fees from AstraZeneca, Eli Lilly, Daiichi Sankyo, The Medicines Company, Accu-Meterics, Boehringer Ingelheim, BMS, Pfizer, Payer, Ferrer, Idorsia. D.R.P.P.C.P.Y., G.-J.A.V., N.M.R.v.d.S., R.W., R.M.T.J.G., D.M.N., J.L., D.M.F.C., M.E.G., J.A., W.L.B., T.O., J.D., G.J.V., R.J.v.B. and Y.A. declare to have no conflict of interest. The funders had no role in the design of the study or in the writing of the manuscript.

Figures

Figure 3
Figure 3
Flowchart illustrating decision-making regarding the optimal treatment duration with dual antiplatelet therapy using risk scores. Abbreviations: ACS, acute coronary syndrome; DAPT, Dual AntiPlatelet Therapy.
Figure 1
Figure 1
Geographical locations of cardiac centers participating in the Future Optimal Research and Care Evaluation in patients with Acute Coronary Syndrome (FORCE-ACS) registry.
Figure 2
Figure 2
Flowchart illustrating data collection in the in Future Optimal Research and Care Evaluation in patients with Acute Coronary Syndrome (FORCE-ACS) registry. Abbreviations: CABG, coronary artery bypass grafting; CV, cardiovascular; PCI, percutaneous coronary intervention; and SF, short form.
See this image and copyright information in PMC

References

    1. Szummer K., Wallentin L., Lindhagen L., Alfredsson J., Erlinge D., Held C., James S., Kellerth T., Lindahl B., Ravn-Fischer A., et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: Experiences from the SWEDEHEART registry 1995–2014. Eur. Heart J. 2017;38:3056–3065. doi: 10.1093/eurheartj/ehx515. - DOI - PMC - PubMed
    1. Szummer K., Wallentin L., Lindhagen L., Alfredsson J., Erlinge D., Held C., James S., Kellerth T., Lindahl B., Ravn-Fischer A., et al. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: Experiences from SWEDEHEART registry 1995 to 2014. Eur. Heart J. 2018;39:3766–3776. doi: 10.1093/eurheartj/ehy554. - DOI - PubMed
    1. Fox K.A.A., Carruthers K.F., Dunbar D.R., Graham C., Manning J.R., De Raedt H., Buysschaert I., Lambrechts D., Van De Werf F. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study) Eur. Heart J. 2010;31:2755–2764. doi: 10.1093/eurheartj/ehq326. - DOI - PubMed
    1. Jernberg T., Hasvold P., Henriksson M., Hjelm H., Thuresson M., Janzon M. Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective. Eur. Heart J. 2015;36:1163–1170. doi: 10.1093/eurheartj/ehu505. - DOI - PubMed
    1. Simonsson M., Wallentin L., Alfredsson J., Erlinge D., Hellstrom Angerud K., Hofmann R., Kellerth T., Lindhagen L., Ravn-Fischer A., Szummer K., et al. Temporal trends in bleeding events in acute myocardial infarction: Insights from the SWEDEHEART registry. Eur. Heart J. 2020;41:833–843. doi: 10.1093/eurheartj/ehz593. - DOI - PubMed

Associated data

Grants and funding

LinkOut - more resources